Background: Edwards Sapien valve is usually implanted through either transfemoral (TF) or transapical (TA) route. We evaluate feasibility and results of implantation of Edwards Sapien valve through Transaortic (TAo) route in patients with aortic stenosis. Methods: Between January 2008 and May 2011 a total of 560 patients underwent TAVI using the Edwards Lifesciences SapienTM valve in our institutions, of which 58 patients (10.4%) underwent a TAo procedure using Ascendra delivery system. All patients were discussed in a multidisciplinary meeting and the decision for TAVI was based on high predictive risk for AVR. Patients with poor vascular access who were considered unsuitable for TF approach were considered for TAo approach if TA approach was either not feasible (3/58) or desirable due to poor lung function (19/58), poor left ventricular function (6/58), fatty heart (2/58) and surgeons preference (28/58). Seven of these patients had also undergone at least one previous heart operation (12.1%). Results: Mean age was 80 ±6.6y and 61% were female (n=23). Mean logistic Euroscore was 32 ±16 and STS score 8.09 ±3. The mean ejection fraction was 45 ±16 %, valve area 0.6 ±0.2cm2 and peak gradient 67 ±19mmHg. All procedures were performed under general anaesthesia. Valve sizes used were 23mm (n=27, 46%), 26mm (n=29, 50%) and 29mm (n=2, 4%). Procedural success was achieved in all patients (100%). Post procedural mean and peak gradients were 6.2 and 11mmHg respectively. None of the patients had more than Grade 1 AR at discharge. None of the patients suffered postoperative stroke or persistent AV block. Incidence of renal failure requiring dialysis was 5.2% (3/58) and major vascular complication was <1% (1/58). The overall 30-day mortality was 7% (4/58). Conclusion: Trans-aortic TAVI is a feasible and safe approach in the treatment of aortic stenosis using Edwards Sapien valve and Ascendra delivery system with low inhospital complication rates. Despite high incidence of respiratory disease the outcome in this subgroup of patients was satisfactory with excellent short-term results.
TCT-136

Twelve-Month Results from the CoreValve Transcatheter Aortic Valve Australia-New Zealand Study
Ian Meredith 1 , Tony Walton 2 , Darren Walters 3 , John Ormiston 4 , Stephen Worthley 5 , Gerald Yong 6 , Robert Whitbourn 7 , Sanjeevan Pasupati 8 , David Muller 9 1 Monash Heart, Melbourne, Australia; 2 The Alfred Hospital, Melbourne, Australia; 3 Prince Charles Hospital, Brisbane, Australia; 4 Mercy Hospital, Auckland, New Zealand; 5 Royal Adelaide Hospital, Adelaide, Australia; 6 Royal Perth Hospital, Perth, Australia; 7 St. Vincent's Hospital, Melbourne, Australia; 8 Waikato Hospital, Hamilton, New Zealand; 9 St. Vincent's Hospital, Darlinghurst, Australia Background: For patients with severe aortic stenosis at high risk for surgical replacement, transcatheter aortic valve implantation (TAVI) is a therapeutic option. We report twelve-month results from a multicenter study in Australia and New Zealand. Methods: The CoreValve (Medtronic, Irvine, Calif.) Australia-New Zealand study is a fully monitored study with independent adjudication of adverse events. The study has enrolled 229 subjects at eight centers since 2008. Inclusion criteria included severe symptomatic aortic valve disease, age >80 or >65 with 1-2 high-risk co-morbidities or logistic EuroSCORE >20. Results: Subjects were male 56%, age 84+6 years, logistic EuroSCORE 18+11, NYHA class III/IV 80%. Procedural success (successful implant without conversion to surgery or death) was 96.9%. Thirty-day all-cause mortality was 4.1% and the stroke rate was 1.9%. In 86 subjects after 12 months, all-cause survival was 88.0+4.5% and cardiac survival was 92.2+3.8%. Valve orifice area and mean gradient showed statistical improvements at 30 days and 12 months. No valve migrations or structural valve deteriorations were reported. Aortic regurgitation grades at 12 months via echo were <2 in 94.0% of patients. Most (76.7%) improved >1 NYHA class at 12 months and only 3.3% worsened.
Conclusion:
The 18Fr CoreValve TAVI prosthesis is safe and effective at twelve months in this monitored and adjudicated multicenter trial. Stable mortality and morbidity outcomes are within expectations for percutaneously treated subjects with severe symptomatic aortic stenosis in this very high-risk subgroup. Enrollment and long-term follow-up are ongoing and updated results, including vascular complications and pacemaker implants, will be forthcoming.
TCT-137
Comparison of Balloon-expandable and Self-expandable Bioprosthesis for Transcatheter Aortic Valve Implantation
Massimo Napodano, Valeria Gasparetto, Chiara Fraccaro, Giuseppe Tarantini, Ermela Yzeiraj, Paolo Buja, Demetrio Pittarello, Augusto D'Onofrio, Gino Gerosa, Giambattista Isabella, Sabino Iliceto Dpt. of Cardiac Thoracic and Vascular Sciences. University of Padova, Padova, Italy Background: Recently Transcatheter Aortic Valve Implantation (TAVI) using balloonexpandable prostheses favorably compared to conservative management in inoperable patients and to surgery in high-risk patients. However, no data in comparison with surgery exists for self-expandable prostheses. We assessed prosthesis performance and clinical outcome of TAVI using self-expandable or balloon-expandable devices. Safety and efficacy end-points were expressed according to VARC definitions. Results: One-hundred and ninety-eight patients underwent TAVI, 87 (43.9%) with CRS (82 transfemoral and 5 trans-subclavian), 111 (46.1%) with ES device (62 transapical and 49 transfemoral). Mean age was 81.0 ± 6.6 years (55.1% female), logistic EuroSCORE of 21.4 ± 13.3%. Procedural success was 94.3% in CRS and 95.5% in ES (p= ns). Back-up strategies to achieve procedural success (re-dilatation, valve snaring or valve-in-valve) was higher in CRS (p= 0.02). Thirty-day mortality was 5.7% in CRS and 2.9% in ES (p= 0.32). Thirty-day combined safety end-point (VARC) was 14.9% in CRS vs 19.2% in ES (p=0.43). AV-block requiring pacemaker implantation were 40.7% in CRS, vs 8.6% in ES (p< 0.001). At follow-up (mean 12.4±9.7 months), 13.6% patients died, 4.0% had cardiovascular death, without differences between groups. However, the combined efficacy endpoint (VARC) at 1year was 31.7% in CRS and 9.8% in ES (p=0.01). At both 48-h and follow-up echocardiograms, effective orifice area was larger in CRS (p= 0.01), and moderate-tosevere paravalvular leak was more frequent in CRS (p= 0.01). Conclusion: TAVI using both self-expandable and balloon-expandable prostheses seems a safe alternative to surgery in high-risk aortic stenosis. However, prosthesis performance as well as 1-year effectiveness were higher using balloon-expandable devices.
TCT-138 Aortic Annulus Diameter Determination by Multidetector Computed Tomography: Reproducibility, Applicability and Implications for Transcatheter Aortic Valve Replacement
Ronen Gurvitch, John Webb, Yen Ruan, Mark Johnson, Cameron Hague, Alexander B Willson, Stefan Toggweiller, David A Wood, Jian Ye, Robert Moss, Christopher Thompson, Jonathon Leipsic St. Paul's Hospital, Vancouver, Canada Background: The reproducibility and applicability of multidetector computed tomography (MdCT) annular measurements to guide transcatheteraortic valve implantation (TAVI) remain unclear. Prior studies desmonstrated discordance between echocardiography and MdCT, suggesting that MdCT guided valve implantation would frequently alter the treatment strategy despite good results with echocardiographic sizing. Methods: Fifty patients underwent MdCT evaluation prior to possible TAVI. Annular measurements were performed in blinded fashion by 3-independent readers in multiple planes. A theoretical model was developed taking into account differences between the most reproducible MdCT measurements and transesophageal echocardiography (TEE) to guide valve size choice. Results: The most reproducible MdCT measurements were the Area Derived Diameter and Basal Ring Average Diameter [inter-reader correlation 0.87(95%C.I 0.81-0.92) and 0.80 (95%C.I 0.70-0.87) respectively, intra-reader >0.90 for all readers]. These measurements were larger than TEE diameters (mean difference 1.5±1.6mm and 1.1±1.7mm respectively). When a strategy of valve sizing based on MdCT measurements but according to current TEE based cutoffs was used, a different valve size was chosen in 44-40% respectively. When adjusting the sizing cutoffs to account for the differences in observed diameters, this was reduced to 10-12% (p<0.01 for both). In cases with persistent discrepancies, the incidence of significant aortic incompetence was as high as 75%. Conclusion: The most reproducible MdCT measurements of the annulus are the Area Derived Diameter and Basal Ring Average Diameter, with values generally larger than those obtained with echocardiography. If MdCT is used for valve sizing, a strategy incorporating these differences appears to be important. MdCT may reduce the incidence of inadvertent undersizing in selected cases.
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